Key result
The ESPRIT trial will randomize 4,500 patients with TIA or minor ischemic stroke to oral anticoagulation, aspirin plus dipyridamole, or aspirin alone to evaluate vascular outcomes over 3 years.
Why the study?
Does oral anticoagulation or dipyridamole plus aspirin reduce vascular death, stroke, MI, or major bleeding compared to aspirin alone in patients with TIA or minor ischemic stroke?
Population
Planned 4,500 patients with a TIA or minor ischaemic stroke (Rankin grade <=3)
Comparison
Oral anticoagulation or combination of… vs Aspirin only
Design
Other, Randomized, Outcome assessment will be blinded
Follow-up
mean 3 years
Authors
Loading...
May resolve optimal antithrombotic strategy after TIA; leaves open superiority of anticoagulation or aspirin-dipyridamole versus aspirin alone.
RCT (n=4,500)
Blinded outcome assessment
Yes
Does oral anticoagulation or dipyridamole plus aspirin reduce vascular death, stroke, MI, or major bleeding compared to aspirin alone in patients with TIA or minor ischemic stroke?
The ESPRIT trial is designed to evaluate whether oral anticoagulation or aspirin plus dipyridamole is superior to aspirin alone for secondary prevention after TIA or minor ischemic stroke.
E.L.L.M. De Schryver (2000) conducted an RCT in Transient ischaemic attack (TIA) or minor ischaemic stroke (n=4,500). Oral anticoagulation or dipyridamole plus aspirin vs. Aspirin only was evaluated on Composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication. The ESPRIT trial will randomize 4,500 patients with TIA or minor ischemic stroke to oral anticoagulation, aspirin plus dipyridamole, or aspirin alone to evaluate vascular outcomes over 3 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: